OneMedNet Corporation announced that its iRWD platform, powered by Palantir Foundry and enhanced with Datavant’s tokenized linkage, is now live and fully operational. The platform offers searchable access to billions of records across 80 million patient journeys, 251 million studies, and links to approximately 47 million tokenized patients, enabling rapid, longitudinally connected, multimodal data exploration.
The launch marks a key milestone in OneMedNet’s strategy to monetize its regulatory‑grade real‑world data network and accelerate AI model development for life‑sciences clients. Two new customers have already contracted for the platform at launch, underscoring early market acceptance. President & CEO Aaron Green said, "The integration of our iRWD™ platform with Palantir Foundry marks a transformative step for OneMedNet. Our subscription customers can now find the data they need in seconds — unlocking a new phase of commercial execution and significantly enhancing our ability to deliver high‑value, decision‑grade data. We are now actively converting a robust pipeline into subscription‑based customers with meaningful annual recurring revenue potential."
Technically, the platform leverages Palantir’s ontology and analytics capabilities to deliver data in seconds, while Datavant’s tokenized linkage ensures patient privacy and longitudinal connectivity. The regulatory‑grade nature of the data positions OneMedNet to support AI model training and validation for pharmaceutical and device manufacturers seeking high‑quality imaging and clinical data.
The iRWD launch represents a strategic pivot toward a subscription‑based ARR model, positioning OneMedNet to capture value from its expanding data network. By providing instant, searchable access to a vast, multimodal dataset, the platform is poised to transform how life‑sciences companies source and analyze real‑world evidence, potentially accelerating drug development timelines and improving clinical decision support.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.